Bipolar I disorder: current and future management options
|
|
- Victor Moody
- 5 years ago
- Views:
Transcription
1 Bipolar I disorder: current and future management options Eduard Maron PhD, MD, Research fellow, Centre for Pharmacology and Therapeutics, Imperial College London; Allan H Young, Professor and Chair of Psychiatry PhD, MD, FRCPsych, FRCPC, Centre for Mental Health, Imperial College London Bipolar I disorder affects around one in every 100 adults and is a major public health issue. It is usually characterised by a combination of manic and depressive symptoms, with severe episodes of mood disturbance that can last for weeks or even months. Both men and women are affected, and the condition is a debilitating one that can adversely influence all areas of a person s life and his/her normal functioning. In this article, the authors look at the disease and its causes, and discuss both current and promising future treatment options. Although bipolar disorder has no single cause, growing evidence suggests that neurotransmitters are likely to be involved in the onset and development of this debilitating illness People with bipolar I disorder, still thought of as classical manic depression, usually experience a mixture of manic and depressive episodes (although a small number will experience mania only). It is distinct from bipolar II disorder, which is characterised by intermittent depressive episodes, and in which the related pathological upswings in mood are only mild and of short duration hypomania. In bipolar I disorder, patients will have experienced at least one manic episode usually lasting longer thana week, with symptoms including: persistently elevated expansive or irritable mood accompanied by features such as grandiosity; a decreased need for sleep; pressure of speech; flight of ideas; distractibility; increased activity; and excessive involvement in pleasur - able activities. Patients will usually also experience at least one major depressive episode during the course of the illness. WHAT CAUSES BIPOLAR DISORDER? Biological factors There is still not a single hypothesis that explains the onset and development of bipolar disorder due to the marked heterogeneity of data from studies exploring neurobiological abnormalities associated with bipolar features. 1 Historically, the monoaminergic neurotransmitter systems, including serotonin, norepinephrine and dopamine, were the main focus of theories and research about the aetiology of mood disorders, but despite growing evidence suggesting that many of these neurotransmitters are likely to be involved in bipolar disorder, no characteristic dysfunction of any single neurotransmitter system has yet been verified. 2 However, both hypothalamic pituitary adrenal (HPA) axis dysfunction and glucocorticoid resistance, which are well recognised in unipolar depression, may reflect a trait-related abnormality in bipolar disorder, given their presence across different phases of the illness, including euthymia and remission F U T U R E P R E S C R I B E R V O L 1 2 ( 3 ) w w w. f u t u r e p r e s c r i b e r. c o. u k
2 More recently, an abundance of research, incorporating diverse levels of scale and investigative techniques from chemical or molecular processes through to neuro imaging of neural networks, have implicated specific neuro - endocrine, neurotransmitter and intracellular signal transduction pathways in the pathophysiology of bipolar illness. In brief, the detected abnormalities in bipolar disorder include elevated protein kinase A activity, altered intracellular calcium signalling, enhanced proinflammatory cytokine pro duction, glucocorticoid receptor dysfunction, reduced prefrontal N-acetylaspartate, white matter abnormalities and impaired functioning of anter - ior limbic and prefrontal neural networks. 1 Genetic factors Combined evidence from family, twin and adoption studies suggests that bipolar disorder has a significant genetic component. Twin studies, for example, show a highly elevated concordance rate in monozygotic twins when compared with dizygotic twins, and bipolar illness is more likely to occur in biological parents of adopted children than in the adoptive parents. 2 Genetic association studies have identified numerous genes that confer vulnerability to bipolar disorder, many of which are known to function in the signalling pathways previously identified as relevant to the aetiology of this illness. 3 PREVALENCE Bipolar illness is a relatively common medical problem. Recent cross-sectional sur veys of community adults in 11 countries in the Americas, Europe and Asia showed that the overall lifetime prevalence was 0.6% for bipolar I, 0.4% for bipolar II and 1.4% for subthreshold bipolar disorder, thus yielding a total bipolar spectrum disorder prevalence estimate of 2.4% worldwide. 4 Also, it should be noted that bipolar disorder is often underdetected, mainly because milder forms of the illness are often missed or misdiagnosed. In contrast to major depressive disorder, bipolar I disorder has an equal prevalence among men and women and an earlier age of onset mean age of around 20 years. 4 Notably, manic episodes are somewhat more common in men and depressive episodes in women; but when manic episodes occur in women, they are more likely than men to present a mixed picture comprising both manic and depressive symptoms. As compared to men, women also have a higher risk of being rapid cyclers, meaning they will have four or more distinct episodes of bipolar disorder in a one-year period. Despite these differences, little research exists regarding gender-specific aetio - pathogenic or treatment considerations. It has also been found that bipolar I disorder is more common in divorced and single persons than among married people, and a higher than average incidence of bipolar illness is found among upper socioeconomic groups. 5 COSTS ASSOCIATED WITH BIPOLAR DISORDER A burden on the NHS Bipolar disorder represents a major public health issue due to its attendant high morbidity and mortality rates, and has been shown to impair both patients Early age of onset (before 25 years) Bipolar family history Agitated or cyclical depression Refractory depression Depression in person with extroverted traits Emotionally unstable personality disorder Faster onset of depressive episodes Hyperthymic temperament Periodic irritability or impulsivity Gambling Sexual misconduct Wanderlust Suicidal crises Table 1. Clinical features predictive of bipolar disorder quality of life and occupational functioning. It is associated with greater healthcare service utilisation and direct medical costs than unipolar depression, being the sixth leading cause of medical disability worldwide among people aged years. 6 9 A recent, retrospective cohort study estimated the direct annual cost of bipolar disorder to the NHS to be 342 million (at 2009/2010 prices). Hospitalisation accounted for 60%, outpatient and community mental health 26.7%, and medication in primary care 7.4% of the overall direct costs of care. 10 Importantly, this figure is larger than the 200 million estimated by the earlier analysis by Das Gupta and Guest, and yet may be an underestimate as it is based on a very conservative measure of prevalence. These data do indicate that, contrary to the anticipated positive impact of introducing the National Institute for Health and Clinical Excellence (NICE; 2006) bipolar guidelines and the Quality and Outcomes Framework (2004), the cost to the NHS of managing this illness has likely increased. w w w. f u t u r e p r e s c r i b e r. c o. u k F U T U R E P R E S C R I B E R V O L 1 2 ( 3 ) 1 5
3 Personal costs People with bipolar I disorder are at an increased risk of having one or more additional co-morbid mental health disorders. Male patients more frequently present with substance misuse, while females more frequently present with co-morbid anxiety and/or eating disorders. In general, the recent Epidemiological Catch ment Area study 11 showed that lifetime history of substance use, panic and obsesive-compulsive disorders was approximately twice as high among patients with bipolar I illness (61%, 21% and 21%, respectively) than in those with unipolar major depression (27%, 10% and 12%, respectively). Acute mania Stop antidepressant treatment Consider antipsychotics or mood stabilisers Combine antipsychotic and valproate or lithium if response is inadequate Monitor compliance, dose and plasma level (lithium, valproate) Consider adding short-term benzodiazepine Consider electroconvulsive therapy if refractory state Depressive episode Consider quetiapine monotherapy Consider lithium and lamotrigine combination Consider olanzapine and fluoxetine combination Consider adding antidepressants Consider electroconvulsive therapy if refractory state Prophylaxis Consider lithium, valproate, quetiapine or olanzapine as first-line prophylactic agents Continue treatment for at least two years Consider SSRI or cognitive behavioural therapy with a mood stabiliser or quetiapine for chronic or recurrent depression Combine lithium and valproate for the prophylaxis of rapid cycling illness See also: Taylor D, Paton C, Kapur S, eds. Prescribing Guidelines, 10th edn. The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust. Table 2. Treatment strategies for bipolar I disorder The mortality rate of the disease is two to three times higher than that of the general population, and the depressive phase of bipolar disorder represents one of the highest risk periods for suicide of all psychiatric illnesses. In particular, the risk that individuals with bipolar disorder will take their own life is 20 times greater than that of the general population, and nearly one-third of patients admit to at least one suicide attempt. 12 A CHALLENGING CONDITION TO TREAT Unfortunately, bipolar disorder is often undiagnosed or misdiagnosed in the clinical and community populations. This has led to a variety of negative consequences, perhaps the most obvious being a delay in effective therapy and, consequently, greater disability. 13 Earlier recognition of bipolar illness has emerged as a major challenge in everyday clinical practice. Patients may, for instance, not seek treatment when they are hypomanic, considering their symptoms to be a facet of everyday life, or may present to the physician while in a depressed phase. Additionally, numerous studies have shown that bipolar disorder is not only confused with personality, substance use and schizophrenic disorders, but also with depressive and anxiety disorders. Therefore, an accurate diagnosis should involve the careful clinical evaluation of patient and family histories, within the context of the number, severity and duration of mood symptoms, as well as the use of screening questionnaires. 13,14 Although there are predictive indicators of bipolarity (see Table 1), none of these confirms a bipolar diagnosis by itself, but should always be considered and raise the clinical index of suspicion. It should also be remembered that <10% of patients with bipolar I disorder experience only manic episodes throughout the course of the disease, and that the majority of patients most often start with depressive manifestations. 5 Impor tantly, bipolar I disorder misdiagnosed as unipolar depression has substantial clinical implications, including an increased risk of rapid cycling and likely increased costs of care, due to delayed use or under-prescription of mood-stabilising medications. Mood-stabilising therapy may be less effective when initiated after unsuccessful therapy for depressive episodes; moreover, antidepressants have been shown to be less effective than mood stabilisers in preventing depressive relapse in bipolar patients and are associated with increased rates of switching to a manic state. 13 MANAGEMENT OF BIPOLAR I DISORDER A number of pharmacotherapies are available for the treatment of bipolar I disorder, and the final therapeutic choice depends on the episode symptoms and severity, patient preference, drug safety and likely side-effects. Particularly, approved and off-label pharmacotherapeutic treatments for bipolar I disorder in the acute manic or depressive phase as well as the maintenance phase include agents such as mood stabilisers, atypical antipsychotics, anticonvulsants and antidepressants (see Table 2). The usefulness of antidepressants in bipolar mood treatment is a subject of continued debate. 15 The successful management of bipolar I disorder requires careful clinical and risk assessment for current and past phases to identify individually more suitable medica- 1 6 F U T U R E P R E S C R I B E R V O L 1 2 ( 3 ) w w w. f u t u r e p r e s c r i b e r. c o. u k
4 tion in order to resolve acute symptoms and prevent further disease development. In many cases, it is likely that combination therapy will be necessary to achieve these objectives. 14 In general, about 50% of individuals with mania respond to monotherapy with an antimanic agent, and 75% may respond to a combination of an atypical anti psychotic and either lithium or valproate. Once a successful acute treatment medication has been found and the mood episode is in remission, treatment must then be geared towards relapse prevention. Lithium still remains the gold standard for the treatment and maintenance of bipolar I disorder, and particularly for protection against suicide in bipolar patients. Data suggest, however, that it is more effective at preventing manic than depressive relapse. 12 A weakness of treatment with conventional mood stabilisers is the delayed onset of action; for example, in randomised controlled trials, separation from placebo may not be observed with lithium until the third week, and sodium valproate is often similarly slow to work. And, in order to avoid toxic effects of lithium, careful monitoring of plasma levels is needed. There is some evidence showing that valproate may be effective in patients who have failed to respond to lithium. 16 Valproate is also recommended 17 as a first-line option for the treatment of acute episodes of mania, in combination with an antidepressant for the treatment of acute episodes of depression, and for prophylaxis, but it should not be routinely used to treat bipolar illness in women of childbearing age due to its teratogenic effect. Atypical antipsychotics are another popular group of medications that may be used to treat all aspects of bipolar disorder. Olanzapine, risperidone, quetiapine and aripiprazole have been most robustly evaluated, and are licensed in the UK for the treatment of mania. Although olanzapine is probably most widely used, associated weight gain, which is linked to an increase in diabetes and metabolic syndromes, can be an issue that compromises treatment in some patients. 6 Despite the current availability of numerous treatment agents for bipolar I disorder, these may not provide sustained symptomatic remission in most, and the long-term outcome of treatment remains poor. A study investigating the outcome of treatment for bipolar disorder showed high rates of morbidity even during mainten ance therapy. 14 On longterm follow-up, 15% of all patients with bipolar I disorder are well, 45% are well but have multiple relapses, 30% are in partial remission and 10% are chronically ill. 5 Treatment is also complicated by problems with patient noncompliance with medication regimens, which may rise to 64% among patients, leading to high relapse and mortality risks. 18,19 Inter est ingly, recent evidence has shown that pharmacologically treated patients with bipolar disorder may also derive significant benefit from group psychoeducation, which may reduce length of hospitalisations and prevent both relapse risk and the number of recurrences. 20 FUTURE TREATMENTS There are a number of new agents, including N-acetylcysteine, omega 3 fatty acids, tamoxifen, asenapine, antiglucocorticoids, celecoxib, mod afinil and pramipexole, which have provided some interesting prelimin - ar y results in bipolar disorder, although further large, placebocontrolled studies are still needed before drawing definitive conclusions on their potential. 21 Despite extensive efforts to identify novel treatment targets for bipolar I disorder, few have demonstrated clearly significant therapeutic efficacy to date. Asenapine Asenapine is a novel atypical antipsychotic with a unique human receptor binding profile. Its mechanism of action involves antagonism at serotonin, dop - amine, noradrenaline and histamine receptors. It has shown promise in initial clinical trials in adults for acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features. Recent studies in bipolar I disorder established the efficacy of asenapine in acute mania when compared with placebo, with superiority of asenapine beginning at day 2, and these studies also supported its good tolerability and therapeutic efficacy in long-term maintenance in bipolar patients. 22,23 This clinical evidence shows that asenapine is an efficacious and well-tolerated treatment option for patients with bipolar I disorder. CONCLUSIONS Bipolar I disorder is a recurring illness, with full-blown manic and depressive episodes frequently interspersed with periods of time with subsyndromal symptoms. It is a relatively common, chronic and disabling psychiatric illness that is w w w. f u t u r e p r e s c r i b e r. c o. u k F U T U R E P R E S C R I B E R V O L 1 2 ( 3 ) 1 7
5 associated with high levels of functional impairment, morbidity, mortality and an increased risk of suicide. It frequently goes unrecognised and undiagnosed, and thus can remain untreated or inappropriately treated. Despite available medications, new agents and/or combination therapies are needed to achieve the goal of achieving and sustaining euthymia in bipolar patients, and there are some interesting new data emerging. The successful future management of patients with bipolar I disorder requires multidisciplinary, systematic and comprehensive assessment of all facets of bipolar illness and a personalised healthcare approach. To enhance the therapeutic outcome in patients with bipolar I disorder, the recommended treatment programme should include the selection of medication on the basis of risk-benefit evaluation, a combination of primary prevention strategies, such as psychoeducation, increased physical activity, diet improvement, and secondar y inter ventions with targeted treatments. Particularly, treatment targets should move beyond acute symptoms and prevention of mood episodes to address cognitive deficits, emotional dysregulation, sleep and circadian problems, improvement of quality of life and general functionality, and the reduction of clinical complications. 24 Such a comprehensive treatment strategy may both improve outcomes and reduce the costs of bipolar disorder. 10 DECLARATION OF INTERESTS Dr Maron has received grants from, and has been a consultant or speaker for, Lundbeck and GlaxoSmithKline. Professor Young has received grants from, and has been a consultant or speaker for, pharmaceutical companies with products licensed for bipolar disorder. REFERENCES 1. Langan C, McDonald C. Mol Psychiatry 2009;14: Martinowich K, et al. J Clin Invest 2009; 119: Kato T. Trends Neurosci 2008;31: Merikangas KR, et al. Arch Gen Psychiatry 2011;68: Sadock BJ, Kaplan HI, Sadock VA, eds. Kaplan and Sadock s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 10th edn. Phila delphia, PA: Lippincott Williams & Wilkins, Frye MA. N Engl J Med 2011;364: Matza LS, et al. J Clin Psychiatry 2005; 66: Reed C, et al. Eur Psychiatry 2010;25: Sajatovic M. Am J Manag Care 2005;11(3 Suppl):S Young AH, Rigney U, Shaw S, et al. Annual cost of managing bipolar disorder to the UK healthcare system. J Affect Disord 2011;133: Das AK, et al. JAMA 2005;293: Baldessarini RJ, et al. Harv Rev Psychiatry 2010;18: Zimmerman M. Expert Rev Neurother 2010;10: Kasper S. Eur Neuropsychopharmacol 2003; 13(Suppl 2):S Nierenberg AA. J Clin Psychiatry 2008;69 (Suppl 5):S Pope HG Jr, et al. Arch Gen Psychiatry 1991;48: Grunze H, et al; WFSBP Task Force On Treatment Guidelines For Bipolar Disorders. World J Biol Psychiatry 2010;11: Colom F, et al. J Clin Psychiatry 2000;61: Schou M. Acta Psychiatr Scand 1997;95: Colom F, et al. Arch Gen Psychiatry 2003; 60: Gao K, Calabrese JR. Bipolar Disord 2005; 7(Suppl 5): McIntyre RS, et al. Bipolar Disord 2009; 11: McIntyre RS, et al. J Affect Disord 2010; 122: Leboyer M, Kupfer DJ. J Clin Psychiatry 2010;71:
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationBipolar Disorder 4/6/2014. Bipolar Disorder. Symptoms of Depression. Mania. Depression
Bipolar Disorder J. H. Atkinson, M.D. Professor of Psychiatry HIV Neurobehavioral Research Programs University of California, San Diego KETHEA, Athens Slides courtesy of John Kelsoe, M.D. Bipolar Disorder
More informationAffective Disorders.
Affective Disorders http://www.bristol.ac.uk/medicalschool/hippocrates/psychethics/ Affective Disorders Depression Mania / Hypomania Bipolar mood disorder Recurrent depression Persistent mood disorders
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationWhat s new in the treatment of bipolar disorder?
What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.
More informationIt's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum
It's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum Session 4022: American Psychiatric Nurses Association National Conference, Louisville, KY Andrew Penn, RN, MS, NP, CNS Psychiatric
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationAging with Bipolar Disorder. Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health
Aging with Bipolar Disorder Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health Objectives Define bipolar disorder in the elderly Review comorbidities How does it differ from bipolar in
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationDepressive and Bipolar Disorders
Depressive and Bipolar Disorders Symptoms Associated with Depressive and Bipolar Disorders Characteristics of mood symptoms Affects a person s well being, school, work, or social functioning Continues
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationasenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd
asenapine 5mg, 10mg sublingual tablet (Sycrest ) SMC No. (762/12) Lundbeck Ltd 10 February 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More informationThe Maudsley Prescribing Guidelines in
The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief
More informationBipolar Disorders. Disclosure Statement. I have no financial disclosures or conflicts of interest
Bipolar Disorders Ahsan Naseem, MD Diplomate American Board of Psychiatry and Neurology Adult and Geriatric Psychiatry Medical Director Bryan Heartland Psychiatry Bryan Physician Network Partner Cheney
More informationComprehensive Quick Reference Handout on Pediatric Bipolar Disorder By Jessica Tomasula
Comprehensive Quick Reference Handout on Pediatric Bipolar Disorder By Jessica Tomasula Official Name Bipolar Disorder; also referred to as Manic Depression Definitions (DSM-IV-TR, 2000) Bipolar I Disorder
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationTreatment of Bipolar disorder
8/6/215 Treatment of Bipolar disorder Pichai Ittasakul, M.D. Department of Psychiatry, Ramathibodi Hospital, Mahidol University Bipolar disorder Manic-depressive Illness. is characterized by the occurrence
More informationDISEASES AND DISORDERS
DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related
More informationThis chapter discusses disorders characterized by abnormalities of mood: namely, Mood Disorders
CHAPTER 1 Mood Disorders Description of mood disorders The bipolar spectrum Can unipolar depression be distinguished from bipolar depression? Are mood disorders progressive? Neurotransmitters and circuits
More informationLithium in bipolar disorders.
Lithium in bipolar disorders. S. Mehdi Samimi Ardestani M.D. Department of Psychiatry, Shahid Beheshti University of Medical Science, Behavioral science research center Iranian psychiatric association,
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary
More informationPractical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current Clinical Guidelines
SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR DISORDER Practical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current s Flavio Guzman, MD Editor Psychopharmacology Institute
More informationA new Anatomy of Melancholy: rethinking depression and resilience
A new Anatomy of Melancholy: rethinking depression and resilience Prof Declan McLoughlin Dept of Psychiatry & Trinity College Institute of Neuroscience Trinity College Dublin St Patrick s University Hospital
More informationMood Disorders Workshop Dr Andrew Howie / Dr Tony Fernando Psychological Medicine Faculty of Medical and Health Sciences University of Auckland
Mood Disorders Workshop 2010 Dr Andrew Howie / Dr Tony Fernando Psychological Medicine Faculty of Medical and Health Sciences University of Auckland Goals To learn about the clinical presentation of mood
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationBipolar disorder. Paz García-Portilla
Bipolar disorder Paz García-Portilla BD I: Epidemiology Life-time prevalence 1% (0.7 1.8%) 30% with diagnosis and without treatment, or with erroneous diagnosis (major unipolar depression, borderline PD)
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationPSYCH 235 Introduction to Abnormal Psychology. Agenda/Overview. Mood Disorders. Chapter 11 Mood/Bipolar and Related disorders & Suicide
PSYCH 235 Introduction to Abnormal Psychology Chapter 11 Mood/Bipolar and Related disorders & Suicide 1 Agenda/Overview Mood disorders Major depression Persistent Depressive Disorder (Dysthymia) Bipolar
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 November 2011 SYCREST 5 mg, sublingual tablet B/60 (CIP code: 415 241-6) B/100 (CIP code: 579 353-1) SYCREST 10
More informationBipolar and Affective Disorders. Harleen Johal
+ Bipolar and Affective Disorders Harleen Johal hkj1g11@soton.ac.uk + Affective (mood) disorders n Depression n Bipolar disorder n Anxiety n Treatment + Depression: Definition n Pervasiveand persistent
More informationBorderline personality disorder: what role for medication?
Borderline personality disorder: what role for medication? Mike Crawford Imperial College London CNWL NHS Foundation Trust m.crawford@imperial.ac.uk Licensed medication for PD Jane, 34, moderately severe
More informationManagement of Bipolar Depression
Management of Bipolar Depression Haresh M. Tharwani, M.D. Associate Clinical Professor Medical Director-DRH & Duke Psychiatry Specialty Clinic of Cary, N.C. Bipolar Disorders (Manic-Depressive illness)
More informationKing s Research Portal
King s Research Portal DOI: 10.1016/j.encep.2016.04.004 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Yang, H., & Young,
More informationCONFLICT OF INTEREST OBJECTIVES BIPOLAR DISORDER, OVERVIEW BIPOLAR DISORDER 3/26/2018 TREATMENT OF RAPID-CYCLING BIPOLAR DISORDER
TREATMENT OF RAPID-CYCLING BIPOLAR DISORDER PAMELA MARCUS, RN,APRN/PMH/BC 14460 Old Mill Rd. #201 Upper Marlboro, Maryland 20772 marcusrn@verizon.net CONFLICT OF INTEREST Ms. Marcus has no conflicts of
More informationSOMEWHERE OVER THE RAINBOW: RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF DEPRESSIVE MIXED STATES
SOMEWHERE OVER THE RAINBOW: RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF DEPRESSIVE MIXED STATES Learning Objectives Impart the importance of screening for the presence of mixed features and family
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationBipolar disorder. Ian M Anderson, 1 Peter M Haddad, 1 2 Jan Scott 3 4 CLINICAL REVIEW
bmj.com Visit BMJ Group s Psychiatry portal at http://www.bmj.com/specialties/psychiatry Bipolar disorder Ian M Anderson, 1 Peter M Haddad, 1 2 Jan Scott 3 4 1 Neuroscience and Psychiatry Unit, University
More informationAffective disorders. Psychiatry. Clinical features. Types
Psychiatry 17 Affective disorders Affective disorders are psychiatric diseases with multiple aspects, including biological, behavioural, social, and psychological factors. Tese are mental disorders that
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationPrescribing medications for people with a personality disorder A service evaluation of a community mental health team
Prescribing medications for people with a personality disorder A service evaluation of a community mental health team Dr Umama Khan, Consultant Psychiatrist Dr Venkatesh Ballagere, Specialist Registrar
More informationBipolar affective disorder
82 Bipolar affective disorder A national clinical guideline 1 Introduction 1 2 Definitions and diagnosis 4 3 Acute treatment 10 4 Maintenance 14 5 Reproductive health issues 18 6 Substance misuse 23 7
More informationPDF created with pdffactory Pro trial version
با ی د ر ا ر وه روا ز ش ی دا ه ع وم ش ی ا ان Treatment Challenges in BD Major depressive episode Mixed states= 20% Rapid cycling= 18% (annually), 31.5% (lifetime) Psychiatric Comorbidity (substance abuse,
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationMood Disorders for Care Coordinators
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis in children and adolescents 1. Which of the following statements best describes episodes of mood disorder among young people: c. Affective volatility
More informationRoles of primary care physicians in managing bipolar disorders in adults
CPG UPDATE Roles of primary care physicians in managing bipolar disorders in adults Awaluddin A, Jali N, Bahari R, Jamil Z, Haron N on behalf of Development Group Clinical Practice Guidelines Management
More informationJonathan Haverkampf BIPOLAR DISORDR BIPOLAR DISORDER. Dr. Jonathan Haverkampf, M.D.
BIPOLAR DISORDER Dr., M.D. Abstract - Bipolar disorder is a condition affecting an individual s affective states (mood). The different flavors of bipolar disorder have in common that there are alterations
More informationPractice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,
Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD
More informationMood Disorders-Major Depression
Mood Disorders Paula Gibbs, MD Assistant Professor Department of Psychiatry Medical Director of 5West Med-Psych University of Utah Hospitals and Clinics Mood Disorders-Major Depression Key Points for Major
More informationAdherence in A Schizophrenia:
Understanding and Diagnosing Bipolar Disorder Treatment Promoting for Bipolar Treatment Disorder Adherence in A Schizophrenia: Resource for Providers Engagement Strategies for Health Care Providers, Case
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationNOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression)
NOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression) 11 APRIL 2013 Josephine Cucchiaro, PhD Vice President Clinical Operations & Project Management Sunovion Pharmaceuticals
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationHealthyPlace s Introductory Guide to Bipolar Disorder. By Natasha Tracy
HealthyPlace s Introductory Guide to Bipolar Disorder By Natasha Tracy 1 Index Introduction Chapter One Bipolar Disorder Basics Chapter Two Bipolar Disorder Diagnosis Chapter Three Treatment of Bipolar
More informationWomen And Bipolar Spectrum Disorders
Women And Bipolar Spectrum Disorders Introduction While bipolar disorder is a mental illness that affects both men and women, clinicians who provide care for female patients with bipolar disorder must
More informationPrescribing for people with a personality disorder. POMH-UK QIP 12b
Prescribing for people with a personality disorder POMH-UK QIP 12b Personality disorder Personality disorders are a heterogeneous group of conditions which vary greatly in their severity Characterised
More informationAPPENDIX 33: HEALTH ECONOMICS ECONOMIC EVIDENCE PROFILES
APPENDIX 33: HEALTH ECONOMICS ECONOMIC EVIDENCE PROFILES 1.1 Case identification assessment of adults with bipolar disorder... 2 1.1.1 Clinical/economic question: Mood Disorder Questionnaire (MDQ) versus
More informationMood Disorders. Gross deviation in mood
Mood Disorders Gross deviation in mood Depression u Affective: Depressed mood (kids-irritability), or anhedonia for 2 weeks minimum. u Cognitive: worthlessness/ guilt, hopelessness, indecisiveness/ concentration,
More informationPost Traumatic Stress Disorder (PTSD) versus Bipolar Disorder: Confusion in the face of chaos.
Post Traumatic Stress Disorder (PTSD) versus Bipolar Disorder: Confusion in the face of chaos. Randall Ricardi D.O. Child and Adolescent Psychiatry Phoenix Children s Hospital 6-24-17 10:50am Disclosures
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationThe treatment of bipolar disorder in adults, children and adolescents
DRAFT FOR CONSULTATION The treatment of bipolar disorder in adults, children and adolescents The paragraphs in the draft are numbered for the purposes of consultation. The final version will not contain
More informationBIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD PROFESSOR DEPARTMENT OF PSYCHIATRY UNIVERSITY
More informationCME Article Ministry of Health Clinical Practice Guidelines: Bipolar Disorder
Clinical Practice Guidelines Singapore Med J 2011; 52(12) : 914 CME rticle Ministry of Health Clinical Practice Guidelines: Bipolar Disorder Mok Y M, Chan H N, Chee K S, Chua T E, Lim B L, Marziyana R,
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationSome newer, investigational approaches to treating refractory major depression are being used.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Depression and Anxiety Disorders Mood and anxiety disorders are common, and the mortality risk is due primarily to suicide, cardiovascular
More informationThe Neurobiology of Mood Disorders
The Neurobiology of Mood Disorders J. John Mann, MD Professor of Psychiatry and Radiology Columbia University Chief, Department of Neuroscience, New York State Psychiatric Institute Mood Disorders are
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder
Zahedan Journal of Research in Medical Sciences Journal homepage: www.zjrms.ir The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients
More informationEarly intervention in Bipolar Disorder
Early intervention in Bipolar Disorder Lakshmi N. Yatham MBBS, FRCPC, MRCPsych Professor of Psychiatry, University of British Columbia, Vancouver, Canada Early Intervention in Bipolar Disorder High Risk
More informationDifferentiating Unipolar vs Bipolar Depression in Children
Differentiating Unipolar vs Bipolar Depression in Children Mai Uchida, M.D. Director, Center for Early Identification and Prevention of Pediatric Depression Massachusetts General Hospital Assistant Professor
More informationStudy Guide Unit 3 Psych 2022, Fall 2003
Psychological Disorders: General Study Guide Unit 3 Psych 2022, Fall 2003 1. What are psychological disorders? 2. What was the main treatment for some psychological disorders prior to the 1950 s? 3. What
More informationWHICH BIPOLAR MEDS TO USE IN PRIMARY CARE?
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences WHICH BIPOLAR MEDS TO USE IN PRIMARY CARE? JOHN KERN 8.16.18 GENERAL DISCLOSURES The University of Washington School
More informationDepression. Content. Depression is common. Depression Facts. Depression kills. Depression attacks young people
Content Depression Dr. Anna Lam Associate Consultant Department of Psychiatry, Queen Mary Hospital Honorary Clinical Assistant Professor Li Ka Shing Faculty of Medicine, The University of Hong Kong 1.
More informationA Critical Review of. Current Guidelines for Bipolar Disorder. R. Hamish McAllister-Williams, MD, PhD, MRCPsych
A Critical Review of Psychobiology Research Group Current Guidelines for Bipolar Disorder R. Hamish McAllister-Williams, MD, PhD, MRCPsych Reader in Clinical Psychopharmacology University of Newcastle
More informationChapter 6 Mood Disorders and Suicide An Overview of Mood Disorders
Page 1 Extremes in Normal Mood Chapter 6 Mood Disorders and Suicide An Overview of Mood Disorders Nature of depression Nature of mania and hypomania Types of DSM-IV Depressive Disorders Major depressive
More informationBrief Notes on the Mental Health of Children and Adolescents
Brief Notes on the Mental Health of Children and Adolescents The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationDSM-5 Criteria: Bipolar Disorders
DSM-5 Criteria: Bipolar Disorders Box 1. Bipolar I Disorder: For a diagnosis of bipolar I disorder, it is necessary to meet the following criteria for a manic episode. The manic episode may have been preceded
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationImproving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
More informationMending the Mind: treatment of the severely mentally ill
Mending the Mind: treatment of the severely mentally ill First, the bad news Mental Illness Prevalence: putting things in perspective --More than 54 million Americans have a mental disorder in any given
More informationCASE 5 - Toy & Klamen CASE FILES: Psychiatry
CASE 5 - Toy & Klamen CASE FILES: Psychiatry A 14-year-old boy is brought to the emergency department after being found in the basement of his home by his parents during the middle of a school day. The
More informationUnderstanding Psychiatry & Mental Illness
Understanding Psychiatry & Steve Ellen Mental Illness MB, BS. M.Med. MD. FRANZCP Head, Consultation, Liaison & Emergency Psychiatry, Alfred Health. Associate Professor, Monash Alfred Psychiatry Research
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationAs we have seen, bipolar disorder is a
LONG-TERM MOOD STABILIZATION: PHARMACOLOGIC TREATMENT STRATEGIES * Susan Simmons-Alling, MSN, APRN, BC ABSTRACT This article focuses primarily on the pharmacologic strategies recommended for bipolar disorder.
More informationDrugs, Society and Behavior
SOCI 270 Drugs, Society and Behavior Spring 2016 Professor Kurt Reymers, Ph.D. Chapter 8 Medication for Mental Disorders 1. Mental Disorders: a. The Medical Model Model: symptoms diagnosis determination
More informationSchizophrenia FAHAD ALOSAIMI
Schizophrenia FAHAD ALOSAIMI MBBS, SSC - PSYCH C ONSULTATION LIAISON PSYCHIATRIST K ING SAUD UNIVERSITY Schizophrenia - It is not a single disease but a group of disorders with heterogeneous etiologies.
More informationNeurobiology of Depression
Chapter 1 Neurobiology of Depression Depression can affect every aspect of life. A patient undergoing a major depressive episode who receives treatment with any antidepressant will often experience symptomatic
More informationCOURSES ARTICLE - THERAPYTOOLS.US
COURSES ARTICLE - THERAPYTOOLS.US Individual Planning: A Treatment Plan Overview for with Individuals Hypomania and Mania in Bipolar Disorder Control Problems. Individual Planning: A Treatment Plan Overview
More informationComparison between Carbamazepine and Divalproate on the Improvement of Clinical Symptoms of Bipolar Mania with Psychotic Feature
International Journal of Clinical sychiatry 2018, 6(2): 34-39 DOI: 10.5923/j.ijcp.20180602.02 Comparison between and on the Improvement of Clinical Symptoms of Bipolar Mania with sychotic Feature Sonny
More informationPsychopathology: Biological Basis of Behavioral Disorders
1 6 Psychopathology: Biological Basis of Behavioral Disorders 16 Psychopathology: Biological Basis of Behavioral Disorders The Toll of Psychiatric Disorders Is Huge Schizophrenia is the major neurobiological
More informationIntro to Concurrent Disorders
CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,
More information